Schedule 13G ownership disclosure

Zentalis Pharmaceuticals, Inc.

Common Stock, $0.001 par value per share · CUSIP: 98943L107

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Eventide Asset Management, LLC

    Shares: 4,475,054.00 · Class: 6.28%

  • Finny Kuruvilla, M.D., Ph. D.

    Shares: 4,475,054.00 · Class: 6.28%

  • Robin C. John

    Shares: 4,475,054.00 · Class: 6.28%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001580642-25-001015
Form type
SCHEDULE 13G/A
Filer
EVENTIDE ASSET MANAGEMENT, LLC
CIK
CIK 1442891
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub